Transcatheter tricuspid valve‐in‐valve implantation for degenerated surgical bioprosthesis
Catheterization and Cardiovascular Interventions · 2023
DOI: 10.1002/ccd.30554 ↗At a glance
Multizentrische Studie in Catheterization and Cardiovascular Interventions, 2023. Written by Jinmiao Chen and 6 co-authors. Institution: Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China. Major MEDLINE topics: Bioprosthesis, Heart Valve Prosthesis Implantation, Heart Valve Prosthesis. Cited 3 times so far (Crossref); 24 references. Funded by: National Natural Science Foundation of China, Shanghai Sailing Program, Clinical Research Fund of Shanghai Municipal Health Commission.
Abstract (original language)
Background
Isolated redo surgery for degenerated tricuspid bioprosthesis is of very high risk. We aimed to evaluate the safety and efficacy of transcatheter valve‐in‐valve (TVIV) implantation using a novel balloon expandable Renato valve.
Methods
A prospective multicenter study was conducted to enroll patients with degenerated tricuspid bioprostheses. A total of 12 patients underwent TVIV implantation using the Renato valve system via transfemoral, transjugular, or transatrial approaches at three institutions from May 2021 to October 2021. All‐cause mortality and hemodynamic performance were evaluated up to 6 months after procedure.
Results
The median age was 68.2 years, and 75.0% were female. Six patients had a history of rheumatic left‐sided valve surgery and late tricuspid valve replacement. The median preoperative Society of Thoracic Surgeons score was 9.9%. The procedures were successful in all cases. Tricuspid regurgitation and paravalvular leak were none or mild in all patients. The median transvalvular gradient decreased from 7.8 mmHg preoperatively to 4.5 mmHg at 6 months after TVIV, respectively. No death occurred and all patients recovered to New York Heart Association functional class I or II during a 6‐month follow‐up.
Conclusions
TVIV implantation with the Renato valve was a safe and effective treatment for degenerated bioprostheses in high‐risk patients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Cardiovascular Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Cardiovascular Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China.
ORCID profiles: Jinmiao Chen
Funding
- National Natural Science Foundation of China
- Shanghai Sailing Program
- Clinical Research Fund of Shanghai Municipal Health Commission
- China Postdoctoral Science Foundation
- Youth Research Fund of Zhongshan Hospital, Fudan University
Cite
APA
Chen, J., Yang, Y., Song, W., Feng, D., Yan, Y., Wang, C., & Wei, L. (2023). Transcatheter tricuspid valve‐in‐valve implantation for degenerated surgical bioprosthesis. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.30554
Vancouver
Chen J, Yang Y, Song W, Feng D, Yan Y, Wang C, et al. Transcatheter tricuspid valve‐in‐valve implantation for degenerated surgical bioprosthesis. Catheterization and Cardiovascular Interventions. 2023. doi:10.1002/ccd.30554
BibTeX
@article{Chen2023,
author = {Chen, Jinmiao and Yang, Ye and Song, Wenyu and Feng, Deguang and Yan, Yang and Wang, Chunsheng and Wei, Lai},
title = {Transcatheter tricuspid valve‐in‐valve implantation for degenerated surgical bioprosthesis},
journal = {Catheterization and Cardiovascular Interventions},
year = {2023},
doi = {10.1002/ccd.30554}
}
EUVIMED